Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for Pediatric NAFLD
NCT03467217Phase 2Terminated
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Oct 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of losartan in non-alcoholic fatty liver disease (NAFLD), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Oct 2018; status: terminated.
02
Drugs
losartan
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03467217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467217.